These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
253 related items for PubMed ID: 9251674
21. [Lipoprotein glycation and glycoxidation: their importance in diabetes mellitus]. Actis Dato SM, Rebolledo OR. Medicina (B Aires); 2000; 60(5 Pt 1):645-56. PubMed ID: 11188909 [Abstract] [Full Text] [Related]
22. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. J Mol Cell Cardiol; 2000 Sep; 32(9):1621-9. PubMed ID: 10966825 [Abstract] [Full Text] [Related]
23. Natural history of atherosclerosis and hyperlipidemia in heterozygous WHHL (WHHL-Hh) rabbits. II. Morphologic evaluation of spontaneously occurring aortic and coronary lesions. Esper E, Runge WJ, Gunther R, Buchwald H. J Lab Clin Med; 1993 Jan; 121(1):103-10. PubMed ID: 8426070 [Abstract] [Full Text] [Related]
24. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, Vlassara H. Circulation; 2004 Jul 20; 110(3):285-91. PubMed ID: 15249511 [Abstract] [Full Text] [Related]
25. Advanced glycation endproducts and cigarette smoking. Nicholl ID, Bucala R. Cell Mol Biol (Noisy-le-grand); 1998 Nov 20; 44(7):1025-33. PubMed ID: 9846884 [Abstract] [Full Text] [Related]
26. Soluble LDL-immune complexes in type 2 diabetes and vascular disease. Turk Z, Sesto M, Skodlar J, Ferencak G, Turk N, Stavljenić-Rukavina A. Horm Metab Res; 2002 Apr 20; 34(4):196-201. PubMed ID: 11987029 [Abstract] [Full Text] [Related]
27. Metabolism of very-low-density lipoprotein and chylomicrons by streptozotocin-induced diabetic rat heart: effects of diabetes and lipoprotein preference. Niu YG, Evans RD. Am J Physiol Endocrinol Metab; 2008 Nov 20; 295(5):E1106-16. PubMed ID: 18780778 [Abstract] [Full Text] [Related]
28. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Chapman MJ, Guérin M, Bruckert E. Eur Heart J; 1998 Feb 20; 19 Suppl A():A24-30. PubMed ID: 9519339 [Abstract] [Full Text] [Related]
29. The myocardial microangiopathy in human and experimental diabetes mellitus. (A microscopic, ultrastructural, morphometric and computer-assisted symbolic-logic analysis). Taşcă C, Stefăneanu L, Vasilescu C. Endocrinologie; 1986 Feb 20; 24(2):59-69. PubMed ID: 3738404 [Abstract] [Full Text] [Related]
30. Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: possible role of oxidised LDL. Norata GD, Tonti L, Roma P, Catapano AL. Nutr Metab Cardiovasc Dis; 2002 Oct 20; 12(5):297-305. PubMed ID: 12616810 [Abstract] [Full Text] [Related]
31. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent? Kanková K. Proc Nutr Soc; 2008 Feb 20; 67(1):60-74. PubMed ID: 18234133 [Abstract] [Full Text] [Related]
32. APA hamster model for diabetic atherosclerosis. 2. Analysis of lipids and lipoproteins. Yamanouchi J, Takatori A, Itagaki S, Kawamura S, Yoshikawa Y. Exp Anim; 2000 Oct 20; 49(4):267-74. PubMed ID: 11109552 [Abstract] [Full Text] [Related]
34. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. Atherosclerosis; 2006 Mar 20; 185(1):70-7. PubMed ID: 16076470 [Abstract] [Full Text] [Related]
39. The hyperlipidemic hamster as a model of experimental atherosclerosis. Nistor A, Bulla A, Filip DA, Radu A. Atherosclerosis; 1987 Nov 20; 68(1-2):159-73. PubMed ID: 3689479 [Abstract] [Full Text] [Related]